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Abstract
Background Blood pressure (BP) management in frail older people is challenging. An randomised controlled trial of largely
non-frail older people found cardiovascular and mortality benefit with systolic (S) BP target<120 mmHg. However, all-cause
mortality by attained BP in routine care in frail adults aged above 75 is unclear.
Objectives To estimate observational associations between baseline BP and mortality/cardiovascular outcomes in a primary-
care population aged above 75, stratified by frailty.
Methods Prospective observational analysis using electronic health records (clinical practice research datalink, n = 415,980).
We tested BP associations with cardiovascular events and mortality using competing and Cox proportional-hazards models
respectively (follow-up ≤10 years), stratified by baseline electronic frailty index (eFI: fit (non-frail), mild, moderate, severe
frailty), with sensitivity analyses on co-morbidity, cardiovascular risk and BP trajectory.
Results Risks of cardiovascular outcomes increased with SBPs>150 mmHg. Associations with mortality varied between non-
frail <85 and frail 75–84-year-olds and all above 85 years. SBPs above the 130–139-mmHg reference were associated with
lower mortality risk, particularly in moderate to severe frailty or above 85 years (e.g. 75–84 years: 150–159 mmHg Hazard
Ratio (HR) mortality compared to 130–139: non-frail HR= 0.94, 0.92–0.97; moderate/severe frailty HR= 0.84, 0.77–
0.92). SBP <130 mmHg and Diastolic(D)BP <80 mmHg were consistently associated with excess mortality, independent
of BP trajectory toward the end of life.
Conclusions In representative primary-care patients aged ≥75, BP<130/80 was associated with excess mortality. Hyperten-
sion was not associated with increased mortality at ages above 85 or at ages 75–84 with moderate/severe frailty, perhaps due
to complexities of co-existing morbidities. The priority given to aggressive BP reduction in frail older people requires further
evaluation.
Keywords: blood pressure, hypertension, frailty,
Key Points
• Large prospective observational study of 415,980 people above 75 years, inclusive of those often excluded from studies.
• The lowest mortality risk in adults above 75 years was at systolic BP 140–160 mmHg and diastolic of 80–90 mmHg.
• There was excess mortality in adults above 75 years with systolic BP <130 mmHg irrespective of baseline frailty.
• Further work is required to evaluate the safety and benefit of BP reduction in frail older people.
• In adults above 75 years with moderate to severe frailty and all above 85 years, there was no increased mortality risk with
hypertension.
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Introduction
Management of blood pressure (BP) in older people is chal-
lenging, particularly with increasing frailty. Hypertension is
the commonest chronic disease in older adults, prevalent
in over 75% above 80 years [1]. Prognosis according to
BP, including high BP, in older age remains uncertain [2]
compared to populations aged below 70. Caution should
be applied when extrapolating randomised controlled trial
(RCT) results, as frail older adults are under-represented in
clinical trials due to limited life expectancy, co-morbidities,
polypharmacy and cognition [3].
RCTs targeting BP in older adults have drawn contrast-
ing conclusions on BP prognosis to observational studies.
BP guidelines reflect uncertainty in RCT translation to
clinical practice, with BP targets for older adults ranging
from ≤130/80 [4] to ≤150/90 mmHg [5] internationally.
Systolic BP Intervention Trial (SPRINT) [6] found that
in largely non-frail older adults eligible to participate, a
tight systolic (S) BP target <120 mmHg reduced mortality
and cardiovascular events compared with that of <140,
albeit with higher rates of kidney injury and syncope [6,7].
However, SPRINT excluded dementia, significant frailty
and nursing home residents. Observational analyses of rep-
resentative older populations have shown excess mortal-
ity with low SBPs [8–10]. In our study of adults above
80 years with hypertension [9], we found SBP<135 mmHg
was associated with raised mortality risk, despite increased
incident cardiovascular events at SBP≥155mmHg. A recent
meta-analysis of observational studies found no mortality
difference in frail older adults with SBP <140 mmHg com-
pared to >140 mmHg, in contrast to reduced mortality in
non-frail <140 mmHg [11]. A previous analysis on SBP
trajectory and frailty status postulated that raised mortality
at lower SBPs could be attributed to BP decline in 48months
prior to death, demonstrating reverse causation [10]; we have
previously shown pre-terminal BP declines for 14–18 years,
which were particularly marked in those with hypertension,
dementia, heart failure and late-life weight loss [12].
In the UK, the electronic frailty index (eFI) [13] is
predominantly used for frailty screening in primary care.
The eFI is a cumulative deficit model in electronic health
records, derived from the Rockwood approach [14]. This
tool classifies 3% of adults above 65 years as severely frail
and 12% as moderately frail [13].
Overall, observational studies have shown excess mortal-
ity at SBP <130 mmHg in older adults and evidence on BP
interventions in frail older people for BPs>140/90mmHg is
limited. Improved understanding of BP prognosis according
to frailty could be essential in moving towards safer, per-
sonalised BP management in older adults [15,16]. Previous
studies have investigated BP effect on mortality outcomes
alone, without cardiovascular outcomes and with broad BP
categories [11,17].
This study tested associations between baseline BP includ-
ing hypertension, all-cause mortality and incident cardio-
vascular outcomes in a large, representative primary-care
cohort aged 75 and above, stratified by eFI frailty, with up
to 10 years of follow-up. Additional analyses examined the
effect of end-of-life BP declines on outcomes.
Methods
Data source
Primary-care data from the clinical practice research datalink
(CPRD) were analysed, matched at source to hospital
episode statistics [18]. CPRD has been found to be
representative for age, sex and ethnicity [18].
Ethical approval was granted by the Independent Scien-
tific Advisory Committee for UKMedicines and Healthcare
Products Regulatory Agency database research.
Study design
This prospective analysis used CPRD data between 1 January
2000 and 14 November 2014. The study start date (index
date) was the point of eligibility, requiring age 75 years and
at least three BP measures in the previous 3 years (Supple-
mentary data Appendix 1). There were no further exclusion
criteria, to keep the study inclusive of representative older
adults and translatable to clinical practice.
Clinical measures
Blood Pressure (BP)
The median SBP and diastolic(D)BP from routine clinical
BP measures over 3 years prior to index date represented
the study exposure. Median was used to reduce the effect
of extreme values during acute illness. The primary analysis
was based on SBP due to superior prognostic value in adults
above 50 years [19]. Values for SBP were assigned 10-mmHg
categories to provide additional detail to previous progno-
sis studies while maintaining sufficient numbers (85–120
(‘<120 mmHg’), 120–129, 130–139, 140–149, 150–159,
160–169, 170–179, ≥180). The SBP reference group was
130–139 mmHg, in keeping with the majority of interna-
tional guidelines for older adults [5,20,21]. DBPwas divided
into categories of mmHg: <80, 80–90 (reference category)
and ≥90 for analysis.
Electronic frailty index (eFI)
The eFI was developed by Clegg et al. [13] according to
the cumulative deficit method [14]. It assesses 36 deficits
(clinical signs, symptoms, diseases, disabilities and impair-
ments) in electronic records and categorises older adults into
fit (non-frail), mild, moderate or severe frailty. The eFI at
index date determined frailty category.
Covariates
Analyses were run in age categories 75–84 and≥85 years and
adjusted for sex, age at index and quintiles of the 2007 Index
of Multiple Deprivation (IMD) [9,12].
Outcomes
The primary outcome was all-cause mortality, obtained from
the UK Office for National Statistics.
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Table 1. Patient characteristics at baseline and prevalent and incident cardiovascular outcomes by electronic frailty status
eFI category
Total (n) Non-frail Mild frailty Moderate frailty Severe frailty
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Baseline eFI (%) 415,980 260,159 (62.5%) 137,772 (33.1%) 17,032 (4.1%) 1,017 (0.2%)
Mean (SD) age (years) 79.5 (5.2) 79.2 (4.8) 80.0 (5.6) 80.8 (6.2) 80.9 (6.4)
Women (%) 245,481 (59.0) 149,371 (57.4) 84,292 (61.1) 11,116 (65.2) 702 (69.0)
Number in most deprived quintile IMD (% in
lowest quintile)
48,525 (11.7) 26,867 (10.3) 18,612 (13.5) 2,846 (16.7) 200 (19.7)
Current or ex-smokers at baseline (%) 206,640 (49.7) 121,856 (46.8) 74,227 (53.9) 9,926 (58.2) 631 (62.0)
Mean BMI at baseline 26.3 26.1 26.7 27.1 27.7
Mean cholesterol at baseline (mmol/L) 5.5 5.6 5.4 5.1 5.0
High cardiovascular risk (%) 156,882 (37.7) 95,498 (36.7) 54,023 (39.2) 6,925 (40.7) 436 (42.9)
Median baseline systolic BP (mmHg) 144 145 142 140 138
Median baseline diastolic BP (mmHg) 80 80 80 77 75
Hypertension diagnosis at baseline (%) 246,818 (59.3) 143,264 (55.1) 90,608 (65.8) 12,177 (71.5) 769 (75.6)
Prevalent myocardial infarction/procedure (%) 27,579 (6.6) 10,772 (4.1) 13,619 (9.9) 2,943 (17.3) 245 (24.1)
Incident myocardial infarction/procedure (%) 27,414 (6.6) 15,313 (5.9) 10,584 (7.7) 1,444 (8.5) 73 (7.1)
Prevalent heart failure (%) 28,148 (6.8) 7,519 (2.9) 15,713 (11.4) 4,501 (24.4) 415 (40.8)
Incident heart failure (%) 19,645 (4.7) 10,879 (4.2) 12,290 (8.9) 1,460 (8.6) 71 (7.0)
Prevalent stroke (%) 52,320 (12.6) 21,273 (8.2) 25,249 (18.3) 5,355 (31.4) 443 (43.5)
Incident stroke (%) 33,940 (8.2) 20,875 (8.0) 11,571 (8.4) 1,416 (8.3) 78 (7.7)
Prevalent dementia (%) 14,647 (3.5) 5,205 (2.0) 7,537 (5.5) 1,749 (10.3) 156 (15.3)
Died within follow-up period (%) 137,117 (33.0) 74,731 (28.7) 53,516 (38.8) 8,302 (48.7) 568 (55.9)
Prevalent disease measured if date of first occurrence preceded index date. Incident disease if date of first occurrence on or after index date.
Secondary outcomes were incident cardiovascular events:
stroke (ischaemic or intracerebral haemorrhage), myocardial
infarction or cardiac revascularisation procedure (MIP) and
heart failure. Diagnoses were based on ICD-10 classification
for stroke and MI and quality of outcomes framework
(QOF), used in UK primary care to generate databases for
specific health conditions (Supplementary data Appendix
18) [22]. The coding system for surgical procedures [23] was
used to capture coronary angioplasty and coronary artery
bypass graft to increase the yield of clinically significant
coronary artery disease.
Statistical analysis
Statistical analysis used Stata v 15.1. Participants were fol-
lowed up for 10 years from index date, until death or study
end date.
Associations between baseline BP and all-cause mortality
were estimated using the Cox proportional-hazards models,
stratified by the eFI frailty. Fine and Gray competing risk
models [24] were used to estimate associations between BP
and incident cardiovascular outcome (stroke, heart failure,
MIP) within the category of eFI frailty, with mortality as
the competing risk.Moderate to severe frailty categories were
combined due to small numbers in the severe frailty category.
Sensitivity analyses
As the selection criteria were intentionally inclusive, we per-
formed sensitivity analyses to estimate outcomes for specific
groups.
A sensitivity analysis was performed adjusted by sex,
IMD, age at index, cardiovascular risk and BP decline.
Cardiovascular risk was estimated at index date as low (never
smoker, cholesterol <5 mmol/L, body mass index (BMI)
<25 kg/m2 or no recorded risk), intermediate (if one or
more of: BMI 25 to <30 kg/m2, ex-smoker, cholesterol
5–6.5 mmol/L) or high (if one or more of: BMI ≥30 kg/m2,
current smoker, cholesterol >6.5 mmol/L). BP decline was
estimated by the difference in median SBP in the 2 years
prior to index date and 3–5 years prior to index. If the
difference was zero or greater than zero, it was assigned to
the ‘no-decline’ BP group, while any decline was assigned to
the ‘decline’ group.
Other sensitivity analyses were conducted using the
75–84 age group to provide sufficient numbers: excluding
the 7,092 participants in the last 6 months of life to remove
the potential effect of the terminal phase, according to
prevalent hypertension, diabetes and heart failure at index
date (established using QOF rules) and without prevalent
cancer (based on prevalent primary-care diagnosis of cancer
not isolated to skin).
Results
Analyses included 415,980 older adults, mean age 79.5 years
old (range 75.0–109.5) and up to 10 years follow-up. Table 1
presents patient characteristics and outcomes by the eFI
frailty. At analysis, baseline 55.1% non-frail had diagnosed
hypertension compared to 75.6% severely frail. Paradoxi-
cally, the median SBP and DBP were lower with increased
frailty (Table 1).
Mortality outcomes
All-cause mortality by SBP, stratified by the eFI category, is
presented in Figure 1 and Supplementary data Appendix 2.
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Figure 1. Hazard ratio of all-cause mortality by attained systolic BP, stratified by eFI frailty status. Adjusted by IMD, sex and age
at index date.
The age category had a larger effect on all-cause mortality
by SBP (HR 3.01 (3.01–3.08)) and DBP (HR 3.06
(3.02–3.10)) than the frailty category (SBP HR 1.55
(1.53–1.56), DBP HR 1.54 (1.54–1.57)). In adults above
85 years, there was no elevated mortality risk associated
with high SBPs, even with ≥180 mmHg. Compared to
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Figure 2. Hazard ratio of cardiovascular outcomes by attained systolic BP (mmHg) in 75–84 age group, stratified by eFI frailty
status.
130–139 mmHg (reference category), older adults with
SBPs of 140–149 (non-frail HR mortality 0.95, 0.93–0.98;
mild frailty 0.88, 0.85–0.91;) or 150–159 mmHg (non-
frail HR 0.94, 0.92–0.97; mild frailty 0.88, 0.85–0.91;
moderate to severe frailty HR 0.84 (0.77–0.92)) had lower
risk of all-cause mortality. Only those in the non-frail or mild
frailty categories had excess mortality associated with high
SBPs, which reached statistical significance at ≥170 mmHg
in the non-frail (170–179 mmHg compared to 130–
139 HR mortality 1.09, 1.04–1.13) and ≥180 mmHg
with mild frailty (180–189 mmHg HR mortality 1.11
(1.04–1.19). Lower SBPs of 120–129, <120 mmHg and
DBP <80 mmHg (Supplementary data Appendix 4) were
associated with increased HR of mortality in all above
75 years, across frailty categories. Elevated DBP did not
affect outcomes for those with established frailty aged 75–84
or those over 85, but DBP ≥90 mmHg was associated with
raised mortality risk in non-frail and mildly frail adults <85
years old.
Cardiovascular outcomes
Associations between BP and cardiovascular outcomes
showed similar trends between 75–84 and 85+ age cate-
gories (Figure 2 and Supplementary data Appendices 5–10),
with increased risk associated with SBPs over 150 mmHg,
which was less significant with increased frailty for heart
failure and stroke.
Sensitivity analyses
Results of tested associations of SBP and outcomes by frailty
status were consistent when adjusted by BP decline and
cardiovascular risk (Supplementary data Appendices 3, 6,
8, 10), with and without diagnosed hypertension (Supple-
mentary data Appendix 11), without heart failure (Supple-
mentary data Appendix 12) and cancer (Supplementary data
Appendix 13), with diabetes (Supplementary data Appendix
4), with stable or declining BP trajectory (Supplementary
data Appendix 15), excluding the last 6 months of life
(Supplementary data Appendix 16) and by smoking status
(Supplementary data Appendix 17).
Discussion
In this large study of routine clinical data from 415,980
population-representative primary-care patients aged 75 years
and above, we have shown that risks of cardiovascular
outcomes increase with SBPs above 150 mmHg across
categories of eFI frailty. However, this was not accompanied
by raised all-cause mortality, particularly for those with
established frailty or above 85 years old. Relative systolic
hypertension (SBP 140–160mmHg) was associated with the
lowest all-cause mortality across all categories of frailty, with
no increased mortality risk with hypertension in moderate
to severe frailty. SBPs below 130 mmHg and DBPs below
80 mmHg were consistently associated with excess mortality
risk, independent of SBP trajectory. This provides com-
pelling evidence that this association is not solely an artefact
of reverse causation associated with terminal BP decline.
The study was inclusive of multimorbidity, frailty, demen-
tia and physical limitations that prevent recruitment to vol-
unteer studies [3]. Exposure status—BP and frailty—were
ascertained prior to incident outcomes, enabling a prospec-
tive analysis design. The mean follow-up was 4.46 years (up
to 10 years), which is longer than existing RCTs. Clinical
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outcomes were from linked primary and secondary care
CPRD data, which have high validity for cardiovascular out-
comes [25], supported by robust national death certification
mortality.
Limitations include the use of observational data, which
cannot provide evidence of the causal effect of BP treatment,
which would require an RCT. Ravindrarajah et al. [10] pre-
viously showed that associations between SBP and mortality
were consistent whether on antihypertensive intervention or
not. BP measurements were obtained under clinical condi-
tions, which tend to result in higher BP measures, [26,27]
than under controlled conditions used in RCTs. However,
these represent BPs that clinicians use and may be more rele-
vant to routine care. The study aimed to be representative of
the older population, thus we had few exclusion criteria. We
report a lower proportion of moderate and severe frailty than
previously identified in CPRD using the eFI [15]. The most
frail may be under-represented due to not achieving three BP
measures in 3 years prior to index date. These data would be
missing not at random: SBP declines with proximity to death
may have resulted in SBP within normal range, therefore
reducing necessity for monitoring or clinicians may have de-
escalated monitoring due to frailty.These BP values are likely
to be lower than the included measures but we cannot be
sure. Sensitivity analyses investigated the effects of conditions
and co-factors with potential to confound, with minimal
change in results. Limited incident cardiovascular events
in the absence of prevalent events led to wide confidence
intervals (CI) for cardiovascular outcomes, particularly in
those aged above 85.
Ravindrarajah et al. [10] previously published an analysis
on BP trajectory, frailty and all-cause mortality using CPRD
data. We found similar results for mortality outcomes by
BP and have built on this work by analysing cardiovascular
outcomes and diastolic BP, as well as by more discrete BP
categories. Ravindrarajah et al. highlighted the declining
trajectory in 48 months prior to death and postulated that
associations between low SBP and increased mortality could
be attributed to reverse causation. However, we have shown
that associations between baseline BP and mortality status
are consistent, independent of BP decline, for excess mortal-
ity at low SBPs and the lack of association between high SBP
and mortality in above 85 years and in those with moderate
to severe frailty age 75–84 years.
A recently published systematic review and meta-analysis
investigated whether the association between BP and mor-
tality varies according to frailty status [11]. It included nine
studies with 21,906 participants above 65 years, with a mean
follow-up of 6 years. It found that SBP <140 mmHg in
non-frail individuals reduced the risk of all-cause mortality
(HR 0.86, 95% CI 0.77–0.96), while in frail participants,
there was no difference in mortality <140 compared to
>140 mmHg (HR 1.02, 95% CI 0.90–1.16). The dif-
ference in our results for non-frail older adults may be
partially explained by a lower age cut-off of 65 years in the
meta-analysis: we have previously shown that adults above
80 years with diagnosed hypertension but with relatively low
co-morbidity have higher mortality at lower SBPs [9]. We
were able to include more frailty categories and categories
of SBP, which may also account for non-frail differences.
In addition, we have shown that cardiovascular outcomes
are increased with elevated SBP. The review focussed on
mortality and suggested more work is required on non-fatal
outcomes.
BP management in frail older people requires balancing
many, often competing, treatment objectives to obtain the
best possible overall outcomes. The data presented confirm
trial evidence from younger groups that SBPs >150 mmHg
increase the risk of cardiovascular outcomes. However, the
data also suggest that BP-attributable cardiovascular out-
comes have limited impact on overall mortality in frail older
people of 75–84 and all above 85 years. This may be due
to complexities of co-existing morbidity. We have previously
shown, for example, that chronic kidney disease is more
strongly predictive of mortality than BP in adults above
70 years [28]. Serious non-cardiovascular conditions may
be associated with lower BPs in frail groups. Our findings,
therefore, imply that management of non-cardiovascular
morbidities may be relatively more important for many older
frail patients.
Conclusion
In a large representative sample in routine primary care,
adults aged above 75 with BP <130/80 experienced higher
mortality than those with SBP 130–139 mmHg and DBP
80–90. Hypertension was not associated with increasedmor-
tality at ages above 85 or 75–84 with moderate/severe frailty.
The relative priority given to aggressive BP reduction in frail
older people requires further evaluation.
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